Patents Assigned to DNAVEC Corporation
-
Publication number: 20190194607Abstract: The problem is to produce functional liver cells usable in testing the metabolism and toxicity of a drug, from pluripotent stem cells. The solution includes a method for producing highly functional liver cells using pluripotent stem cells, comprising, from pluripotent stem cells, acquiring primitive endoderm derived from the pluripotent stem cells by a process involving steps (A) and (B), from the primitive endoderm, acquiring liver precursor cells by a process involving step (C), and, from the liver precursor cells, acquiring the highly functional liver cells by a process involving step (D): (A) culturing under serum-free and feeder-free conditions; (B) culturing in the presence of albumin and at least one kind of cytokine; (C) culturing in the presence of SHH or an SHH agonist and at least one kind of cytokine; and (D) culturing and maturing in the presence of at least one kind of cytokine.Type: ApplicationFiled: January 30, 2012Publication date: June 27, 2019Applicants: DNAVEC CORPORATION, NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINEInventors: Akira Yuo, Kumiko Saeki, Naoko Nakamura, Satoko Matsuyama, Miwako Nishio, Koichi Saeki, Mamoru Hasegawa
-
Patent number: 9447432Abstract: An object of the present invention is to provide methods for producing iPS cells with low invasivity and high efficiency. The iPS cells can be produced with high efficiency using a method comprising the steps of culturing mononuclear cells derived from peripheral blood for 3 to 14 days in the presence of anti-CD3 antibody, and subjecting the cultured mononuclear cells to dedifferentiation.Type: GrantFiled: April 15, 2011Date of Patent: September 20, 2016Assignees: Keio University, DNAVEC CorporationInventors: Keiichi Fukuda, Shinsuke Yuasa, Tomohisa Seki, Mamoru Hasegawa
-
Patent number: 9127256Abstract: An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.Type: GrantFiled: July 16, 2009Date of Patent: September 8, 2015Assignee: DNAVEC CORPORATIONInventors: Noemi Fusaki, Hiroshi Ban, Mamoru Hasegawa, Yoshikazu Yonemitsu
-
Patent number: 9090909Abstract: The present invention provides Sendai virus vectors in which genes that encode reprograming factors for inducing pluripotent stem cells are incorporated in a specific order, compositions comprising these vectors for gene delivery to be used in the induction of pluripotent stem cells, and uses thereof. Incorporation of the KLF gene, OCT gene, and SOX gene in a specific order into a single Sendai virus vector successfully and significantly increased the efficiency of pluripotent stem cell induction. Loading multiple reprogramming factors into a single vector can further increase the induction efficiency of pluripotent stem cells while reducing the number of necessary vectors.Type: GrantFiled: August 30, 2011Date of Patent: July 28, 2015Assignee: DNAVEC CORPORATIONInventors: Hiroshi Ban, Yasuji Ueda, Noemi Fusaki, Koichi Saeki, Mamoru Hasegawa
-
Patent number: 8741639Abstract: An objective of the present invention is to provide methods for producing dendritic cells (DCs), which comprise the step of culturing DC precursor cells in the presence of a plurality of cytokines, produced dendritic cells, and uses thereof. The present inventors discovered that dendritic cells with a high IL-12 productivity can be obtained by culturing DC precursor cells in the presence of a plurality of cytokines, followed by about one week of culture in the presence of GM-CSF and IL-4. The present invention enables preparation of a large amount of DCs with a high IL-12 productivity from a small number of DC precursor cells, and therefore makes it easier to increase the number of DCs for administration in DC-based anti-tumor immune therapy, treatment of infections, etc. Thus, the effect of DC vaccines is expected to be enhanced.Type: GrantFiled: November 13, 2009Date of Patent: June 3, 2014Assignee: DNAVEC CorporationInventors: Yoshikazu Yonemitsu, Yasuji Ueda, Yui Harada
-
Publication number: 20130210150Abstract: The present invention provides Sendai virus vectors in which genes that encode reprograming factors for inducing pluripotent stem cells are incorporated in a specific order, compositions comprising these vectors for gene delivery to be used in the induction of pluripotent stem cells, and uses thereof. Incorporation of the KLF gene, OCT gene, and SOX gene in a specific order into a single Sendai virus vector successfully and significantly increased the efficiency of pluripotent stem cell induction. Loading multiple reprogramming factors into a single vector can further increase the induction efficiency of pluripotent stem cells while reducing the number of necessary vectors.Type: ApplicationFiled: August 30, 2011Publication date: August 15, 2013Applicant: DNAVEC CorporationInventors: Hiroshi Ban, Yasuji Ueda, Noemi Fusaki, Koichi Saeki, Mamoru Hasegawa
-
Publication number: 20130189786Abstract: An object of the present invention is to provide methods for producing iPS cells with low invasivity and high efficiency. The iPS cells can be produced with high efficiency using a method comprising the steps of culturing mononuclear cells derived from peripheral blood for 3 to 14 days in the presence of anti-CD3 antibody, and subjecting the cultured mononuclear cells to dedifferentiation.Type: ApplicationFiled: April 15, 2011Publication date: July 25, 2013Applicants: Dnavec Corporation, Keio UniversityInventors: Keiichi Fukuda, Shinsuke Yuasa, Tomohisa Seki, Mamoru Hasegawa
-
Patent number: 8283163Abstract: The present invention provides methods for producing DCs, which comprise the step of culturing DC precursor cells in the presence of multiple cytokines, dendritic cells produced thereby, and uses thereof. The methods of the present invention enable production of large quantities of DC precursors with a high ability to differentiate into DCs. The present invention enables one to obtain large quantities of DCs from a small number of DC precursor cells, and therefore makes it easier to increase the number of DCs for administration in DC-based anti-tumor immunotherapy, treatment of infection, and such. Thus, an enhancement is expected for the effect of DC vaccines.Type: GrantFiled: May 12, 2008Date of Patent: October 9, 2012Assignees: DNAVEC CorporationInventors: Makoto Inoue, Mamoru Hasegawa, Yoshikazu Yonemitsu, Yui Harada
-
Publication number: 20120087940Abstract: The present invention provides methods for efficiently inducing anti-A? antibody and methods for preventing and treating Alzheimer's disease. The present inventors successfully induced anti-A? antibody in a highly efficient manner by administering an RNA viral vector that expresses a fusion protein between an AB5 toxin B subunit and an A? antigen peptide. Administration of the vector resulted in a significant increase of anti-A? antibody in plasma, and decrease in the A? level in brain tissues and decrease in the anti-A? antibody-positive area. The present invention enables more efficient vaccine gene therapy for preventing and treating Alzheimer's disease.Type: ApplicationFiled: October 30, 2009Publication date: April 12, 2012Applicant: DNAVEC CorporationInventors: Makoto Inoue, Koichi Saeki, Jun You, Toshiaki Tabata, Hitoshi Iwasaki, Tsugumine Shu, Mamoru Hasegawa
-
Publication number: 20120040458Abstract: An objective of the present invention is to provide methods for producing dendritic cells (DCs), which comprise the step of culturing DC precursor cells in the presence of a plurality of cytokines, produced dendritic cells, and uses thereof. The present inventors discovered that dendritic cells with a high IL-12 productivity can be obtained by culturing DC precursor cells in the presence of a plurality of cytokines, followed by about one week of culture in the presence of GM-CSF and IL-4. The present invention enables preparation of a large amount of DCs with a high IL-12 productivity from a small number of DC precursor cells, and therefore makes it easier to increase the number of DCs for administration in DC-based anti-tumor immune therapy, treatment of infections, etc. Thus, the effect of DC vaccines is expected to be enhanced.Type: ApplicationFiled: November 13, 2009Publication date: February 16, 2012Applicants: Yasuji UEDA, DNAVEC CorporationInventors: Yoshikazu Yonemitsu, Yasuji Ueda, Yui Harada
-
Publication number: 20100323428Abstract: An objective of the present invention is to provide attenuated minus-strand RNA viruses. The present inventors discovered that the amino acid mutation at position 1214 (Y1214F) in the amino acid sequence of L protein of Sendai virus suppressed the viral genome replication activity and/or transcription activity. The inventors also found that the deletion of a particular gene from the viral genome could result in much less cytotoxicity and immune response than conventional. The inventors thus completed the present invention.Type: ApplicationFiled: February 7, 2008Publication date: December 23, 2010Applicant: DNAVEC CORPORATIONInventors: Mariko Yoshizaki, Makota Inoue, Mamoru Hasegawa
-
Publication number: 20100209974Abstract: The present inventors succeeded in producing non-replicating SeV vectors whose genomic RNAs lack all genes for the NP, P, and L proteins, which are RNP-constituting proteins. The present inventors confirmed that the NP/P/L-deficient SeV vectors carrying a marker gene such as GFP provide high productivity, and high transfer and expression efficiencies of foreign genes (high MOI infection is essential for achieving high expression levels). By lacking the L gene or two or more of the NP, P, and L genes, the vectors of the present invention enable lowering the level of virus-derived proteins expressed in host cells, thereby reducing the immunogenicity upon in vivo administration.Type: ApplicationFiled: July 3, 2007Publication date: August 19, 2010Applicant: DNAVEC CorporationInventors: Jun You, Makoto Inoue, Mamoru Hasegawa
-
Publication number: 20100203027Abstract: An objective of the present invention is to provide safe viral vectors for gene therapy that can be introduced by a simple technique and sufficiently express genes of interest in vivo. The present inventors demonstrated that anti-tumor effect can be produced when a heparin-binding cytokine such as granulocyte macrophage colony stimulating factor (GM-CSF) and a chemokine such as TARC or RANTES are expressed in vivo using a viral vector based on a negative-strand RNA virus. The present inventors also demonstrated that the protective effect of the vector is superior to that of conventional adenovirus vectors. Thus, the present invention relates to negative-strand RNA viral vectors comprising a cytokine gene and a chemokine gene. The viral vectors are suitable for treatment of cancers, in particular, metastatic cancers. The present invention also provides compositions comprising such viral vectors, and gene therapy methods using them.Type: ApplicationFiled: April 25, 2008Publication date: August 12, 2010Applicants: Kyushu Univeristy National University, DNavec CorporationInventors: Kenzaburo Tani, Hiroyuki Inoue, Makoto Inoue, Hiroaki Kinoh, Mamoru Hasegawa
-
Publication number: 20100184214Abstract: The present invention provides methods for producing DCs, which comprise the step of culturing DC precursor cells in the presence of multiple cytokines, dendritic cells produced thereby, and uses thereof. The methods of the present invention enable production of large quantities of DC precursors with a high ability to differentiate into DCs. The present invention enables one to obtain large quantities of DCs from a small number of DC precursor cells, and therefore makes it easier to increase the number of DCs for administration in DC-based anti-tumor immunotherapy, treatment of infection, and such. Thus, an enhancement is expected for the effect of DC vaccines.Type: ApplicationFiled: May 12, 2008Publication date: July 22, 2010Applicants: DNAVEC Corporation, Yasuji UEDA,Inventors: Makoto Inoue, Mamoru Hasegawa, Yoshikazu Yonemitsu, Yui Harada
-
Publication number: 20100167341Abstract: The present inventors devised a protein expression system with coexisting MiniSeV and SeV particles, and assessed the system for the ability to transfer a gene(s) of interest into target cells, and to express the gene(s) in the target cells. It was shown that the expression system of the present invention had a high ability to transfer a gene(s) of interest into target cells, and a high ability to express the gene(s) in the target cells.Type: ApplicationFiled: January 17, 2007Publication date: July 1, 2010Applicant: DNAVEC CorporationInventors: Jun You, Toshiaki Tabata, Makoto Inoue, Tsugumine Shu, Mamoru Hasegawa
-
Publication number: 20090246170Abstract: The present invention provides novel therapeutic methods and agents for treating Alzheimer's disease. Specifically, the present invention relates to anti-inflammatory cytokines, anti-inflammatory cytokine genes, negative-strand RNA viral vectors carrying an anti-inflammatory cytokine gene, which are used for treating Alzheimer's disease or developing therapeutic agents for Alzheimer's disease. The present invention also provides pharmaceutical compositions for treating or preventing Alzheimer's disease, which comprise the cytokines or vectors. The present invention further provides methods for treating Alzheimer's disease, which comprise the step of administering an anti-inflammatory cytokine, or a vector such as a negative-strand RNA viral vector carrying an anti-inflammatory cytokine gene. The present invention enables novel gene therapies for Alzheimer's disease.Type: ApplicationFiled: May 31, 2007Publication date: October 1, 2009Applicant: DNAVEC CorporationInventors: Makoto Inoue, Yumiko Tokusumi, Hitoshi Iwasaki, Hiroto Hara, Toshiaki Tabata, Mamoru Hasegawa
-
Publication number: 20090233988Abstract: The present invention provides novel methods for treating diseases associated with apoptotic degeneration in ocular tissue cells by effective administration of pigment epithelium derived factor (PEDF). The present inventors studied PEDF as a means to prevent ganglion cell death, the final pathology of glaucoma. The present invention is particularly focused on SIV vectors for effective methods for delivering PEDF, and constructed an SIV-PEDF vector. When the SIV-PEDF vector was administered subretinally to an ischemia reperfusion model and NMDA-induced model, a significant suppression effect on ganglion cell death was observed. The present inventors therefore discovered that the SIV-PEDF vector is an effective pharmaceutical agent for treating diseases associated with apoptotic degeneration in ocular tissue cells, such as glaucoma.Type: ApplicationFiled: February 21, 2006Publication date: September 17, 2009Applicant: DNAVEC CORPORATIONInventors: Masanori Miyazaki, Yoshikazu Yonemitsu, Yasuhiro Ikeda, Katsuo Sueishi, Toshiaki Tabata, Akihiro Iida, Yasuji Ueda, Mamoru Hasegawa
-
Publication number: 20090170798Abstract: An objective of the present invention is to provide a safe and effective vaccine therapy for Alzheimer's disease. A minus strand RNA viral vector carrying amyloid gene was constructed, and administered intranasally to 24- to 25-months-old APP transgenic mice. The level of serum anti-A 42 antibody was determined and showed to be markedly higher than the control. The results of histological investigation showed that the administration of a vector of the present invention markedly reduced senile plaques in all of the frontal lobe, parietal lobe, and hippocampus. The brain A level was also markedly reduced. Furthermore, the administration of a vector of the present invention did not result in lymphocyte infiltration in the central nervous system.Type: ApplicationFiled: April 20, 2006Publication date: July 2, 2009Applicants: JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY, DNAVEC CORPORATIONInventors: Hideo Hara, Takeshi Tabira, Yoshikazu Yonemitsu, Makoto Inoue, Yumiko Tokusumi, Mamoru Hasegawa
-
Publication number: 20090162320Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.Type: ApplicationFiled: October 27, 2006Publication date: June 25, 2009Applicant: DNAVEC CorporationInventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa